Martínez-Vergara Adrián, Girón Moreno Rosa Mª, Olveira Casilda, Victoria Girón María, Peláez Adrián, Ancochea Julio, Oscullo Grace, Martínez-García Miguel Ángel
Instituto de Investigación Sanitaria La Princesa, Hospital Universitario La Princesa, 28006 Madrid, Spain.
Facultad de Medicina, Universidad Autónoma de Madrid, 28049 Madrid, Spain.
Antibiotics (Basel). 2022 Aug 12;11(8):1096. doi: 10.3390/antibiotics11081096.
Infection by SARS-CoV-2 has unquestionably had an impact on the health of patients with chronic respiratory airway diseases, such as COPD and asthma, but little information is available about its impact on patients with bronchiectasis. The objective of the present study was to analyze the effect of the SARS-CoV-2 pandemic on the state of health, characteristics, and clinical severity (including the number and severity of exacerbations) of patients with non-cystic fibrosis bronchiectasis.
This study was multicenter, observational, and ambispective (with data collected before and during the SARS-CoV-2 pandemic), and included 150 patients diagnosed with non-cystic fibrosis bronchiectasis.
A significant drop was observed in the number and severity of the exacerbations (57% in all exacerbations and 50% in severe exacerbations) in the E-FACED and BSI multidimensional scores, in the pandemic, compared with the pre-pandemic period. There was also a drop in the percentage of sputum samples positive for pathogenic microorganisms in general (from 58% to 44.7%) and, more specifically, (from 23.3% to 13.3%) and (from 21.3% to 14%).
During the SARS-CoV-2 period, a significant reduction was observed in the exacerbations, severity, and isolations of pathogenic microorganisms in patients with bronchiectasis.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染无疑对慢性呼吸道疾病患者的健康产生了影响，如慢性阻塞性肺疾病（COPD）和哮喘，但关于其对支气管扩张症患者的影响，目前所知甚少。本研究的目的是分析SARS-CoV-2大流行对非囊性纤维化支气管扩张症患者的健康状况、特征和临床严重程度（包括急性加重的次数和严重程度）的影响。
本研究为多中心、观察性、双期前瞻性研究（收集SARS-CoV-2大流行之前和期间的数据），纳入了150例诊断为非囊性纤维化支气管扩张症的患者。
与大流行前相比，在大流行期间，E-FACED和BSI多维评分中急性加重的次数和严重程度显著下降（所有急性加重下降57%，严重急性加重下降50%）。一般来说，痰样本中致病微生物呈阳性的百分比也有所下降（从58%降至44.7%），更具体地说，[此处原文有缺失内容]（从23.3%降至13.3%）和[此处原文有缺失内容]（从21.3%降至14%）。
在SARS-CoV-2流行期间，支气管扩张症患者的急性加重、严重程度和致病微生物的检出率显著降低。
